Influence of disease modifying treatment, severe acute respiratory syndrome coronavirus 2 variants and vaccination on coronavirus disease 2019 risk and outcome in …
JJ Eisler, G Disanto, R Sacco, C Zecca… - Journal of Clinical …, 2023 - mdpi.com
Patients suffering from neuro-inflammatory diseases such as multiple sclerosis (MS) and
neuromyelitis optica spectrum disorders (NMOSD) remain vulnerable to COVID-19. We …
neuromyelitis optica spectrum disorders (NMOSD) remain vulnerable to COVID-19. We …
Long-term immune response profiles to SARS-CoV-2 vaccination and infection in people with multiple sclerosis on anti-CD20 therapy
C Woopen, M Dunsche, GK Al Rahbani, A Dillenseger… - Vaccines, 2023 - mdpi.com
Our objective was to analyze longitudinal cellular and humoral immune responses to severe
acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination in people with multiple …
acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination in people with multiple …
Three to four mRNA COVID‐19 vaccines in multiple sclerosis patients on immunosuppressive drugs: Seroconversion and variant neutralization
C Louapre, L Belin, S Marot, A Hippolyte… - European Journal of …, 2023 - Wiley Online Library
Background and purpose An enhanced severe acute respiratory syndrome coronavirus 2
(SARS‐CoV‐2) vaccine regimen could improve humoral vaccine response in patients with …
(SARS‐CoV‐2) vaccine regimen could improve humoral vaccine response in patients with …
Clinical features and outcomes in adults with COVID-19 during the pre-Omicron and Omicron waves
M Martinot, A Schieber, JC Ongagna, A Henric… - Infectious Diseases …, 2024 - Elsevier
Objectives We conducted a single-center retrospective study to compare patient
characteristics and death rates during the Omicron (O, December 01, 2021, to September …
characteristics and death rates during the Omicron (O, December 01, 2021, to September …
[HTML][HTML] Anti-RBD Antibody Levels and IFN-γ-Specific T Cell Response Are Associated with a More Rapid Swab Reversion in Patients with Multiple Sclerosis after the …
This study investigated the incidence and severity of SARS-CoV-2 breakthrough infections
(BIs) and the time to swab reversion in patients with multiple sclerosis (PwMS) after the …
(BIs) and the time to swab reversion in patients with multiple sclerosis (PwMS) after the …
Clinical effectiveness of coronavirus disease 2019 vaccination in patients with multiple sclerosis stratified by disease‐modifying treatment
M De Troyer, A Van Remoortel… - European Journal of …, 2024 - Wiley Online Library
Background and purpose Coronavirus disease 2019 (COVID‐19) vaccination has been
associated with a dampened humoral and/or cellular immune response in patients with …
associated with a dampened humoral and/or cellular immune response in patients with …
Breakthrough COVID-19 infection in people with MS after SARS-CoV-2 vaccination: Should we still be concerned?
ZLE Van Kempen, V Mazziotti - Multiple Sclerosis Journal, 2023 - journals.sagepub.com
In this current issue of Multiple Sclerosis Journal, two separate research groups report on
COVID-19 breakthrough after SARS-CoV-2 vaccination in PwMS. Wood et al. 7 evaluated …
COVID-19 breakthrough after SARS-CoV-2 vaccination in PwMS. Wood et al. 7 evaluated …
Analysis of Evusheld Safety and Efficacy in Multiple Sclerosis Patients
EN Liu, M Real, JH Yang, A Fair, N Whitmire… - Multiple Sclerosis and …, 2024 - Elsevier
ABSTRACT Background In December 2021, the US Food and Drug Administration issued
emergency use authorization for the combination monoclonal antibodies tixagevimab and …
emergency use authorization for the combination monoclonal antibodies tixagevimab and …
Longitudinal increase of humoral responses after four SARS-CoV-2 vaccinations and infection in MS patients on fingolimod
ZLE van Kempen, KPJ van Dam… - Multiple Sclerosis …, 2024 - journals.sagepub.com
Background: Humoral responses after SARS-CoV-2 vaccination are greatly impaired in
multiple sclerosis (MS) patients on fingolimod. Effects of repeated vaccination and infections …
multiple sclerosis (MS) patients on fingolimod. Effects of repeated vaccination and infections …
Clinical and humoral responses after SARS-CoV-2 breakthrough infections in patients with immunosuppressants
EW Stalman, L Wieske, JBD Keijser… - Journal of Allergy and …, 2024 - Elsevier
Background Despite impaired humoral responses in patients treated with
immunosuppressants (ISPs), recent studies found similar severity of SARS-CoV-2 …
immunosuppressants (ISPs), recent studies found similar severity of SARS-CoV-2 …